Brian McNamara, CEO of Haleon plc, recently discussed the company’s strategic journey and evolving priorities at the 23rd annual dbAccess Global Consumer Conference. Speaking in Paris, McNamara provided insights into Haleon’s development since its separation from GSK and its path forward.
Strategic Priorities and Company Evolution
McNamara, who has led Haleon for approximately four years, outlined a phased approach to the company’s development. He noted that the initial phase, post-listing in July 2022, focused on establishing independence from GSK and ensuring business continuity. This involved delivering on growth commitments, building essential corporate functions such as tax and treasury, and assembling a new board.
A significant undertaking during this period was addressing the company’s financial structure. McNamara highlighted the successful reduction of a 4x leverage ratio and the resolution of a substantial overhang from previous owners, Pfizer and GSK. He stated that within two years of its separation, Haleon had effectively “stood up” the company, reduced leverage to around 2.5x, and cleared these ownership-related challenges.
Leadership and Future Potential
Following the foundational work, McNamara indicated that the subsequent phase involved building out a specialized leadership team. He explained that while the team instrumental in the separation was highly capable, a different group of individuals was needed to unlock Haleon’s full potential. This strategic recruitment drive began a couple of years ago, with the initial hire being Namrata Patel as the head of supply chain. As of the conference, 15 members of McNamara’s executive team had been appointed, with 13 of them joining in this later phase.
The discussion, facilitated by Tom Sykes of Deutsche Bank AG’s Research Division, explored these strategic shifts, underscoring Haleon’s commitment to sustained growth and operational excellence in the consumer healthcare market.
